RCS - Highlight Theraptcs. - BO-112 melanoma Phase 2b clinical trial results

Iqvia HoldingsAnnouncement

13/04/2022 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220413:nRSM2493Ia&default-theme=true

RNS Number : 2493I  Highlight Therapeutics  13 April 2022

Highlight Therapeutics announces follow-up results from Phase 2b study of
BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR

 

BO-112 demonstrates potential as new and highly effective second line therapy
for melanoma

 

·    BO-112 demonstrates potential as best-in-class therapy to overcome
anti-PD1 resistance in melanoma patients whose disease has progressed on prior
anti-PD-1 treatment

·    Primary endpoint met with a 30% Response Rate, 15% Complete Responses
(CR) and 65% Disease Control Rate (DCR) substantially exceeding current
standard of care

·    Further improvements anticipated over one year follow up

·    Hard-to-treat mucosal melanoma patients achieved 66% Overall Response
Rate (ORR) and 100% DCR

·    Durable responses and manageable safety profile, with no patients
discontinuing due to adverse events

·    Potential for use in multiple solid cancers resistant to anti-PD1
inhibitors, and with different anti-PD1 combinations

 

Madrid, Spain, 13 April, 2022 - Highlight Therapeutics ("Highlight"), a
clinical-stage biopharmaceutical company developing RNA-based therapies
against cancer, today announced positive results of a Phase 2 study of
intratumoral administration of BO-112 with pembrolizumab in patients with
advanced melanoma whose disease had progressed on first-line anti-PD1-based
therapy. BO-112 is a dsRNA agonist targeting anti-PD1 resistance, which has
demonstrated anti-cancer activity in previous Phase 1b studies.

 

Results of the study were presented at the plenary session at the American
Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans,
Louisiana by Iván Marquez-Rodas (CT014. Efficacy of intratumoral BO-112 with
systemic pembrolizumab in patients with advanced melanoma refractory to
anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 study. 10:15
-12:15 PM CT)

 

Sales of anti-PD1 therapies are valued at approximately $24 billion(1) a year
and they are used to treat most solid tumors. However, currently fewer than
20% of all cancer patients benefit from first-line anti-PD1 treatment. BO-112
in combination with anti-PD1 therapy is designed to resensitize tumors to
anti-PD1 treatment through improved antigen presentation, enhanced T-cell
infiltration and increased MHC-1 and PDL1 expression by the tumor itself.

 

"This remarkable data confirms that BO-112 is effective at resensitizing
tumors and helping to overcome anti-PD1 resistance, opening up the potential
to treat many more patients with anti-PD1 therapies. Analysis of the data
showed that most patients achieved a response rate of 40%, although patients
with very high LDH levels and acral melanoma did not obtain clinical benefit."
Dr. Marisol Quintero, CEO of Highlight Therapeutics, commented. "Importantly,
BO-112 was able to achieve improvements even in patients who had initially
responded to anti-PD1 therapy before regressing and in hard-to-treat mucosal
melanoma, overall response rates of 66% and disease control rates of 100% were
seen, greatly exceeding current standard of care."

 

Highlight Therapeutics and Merck, known as MSD outside the United States and
Canada, conducted an open-label, single arm study to evaluate the efficacy
& safety of intra-tumoral administration of BO-112 + pembrolizumab in
mucosal, acral and cutaneous melanoma patients whose disease had progressed,
confirmed by two consecutive CT scans. The study recruited 42 patients in
France and Spain, with recruitment completed by August 24, 2021. Patients
included those with high LDH levels, which are often associated with poor
response rates and have been excluded from comparable clinical trials.

 

The analysis shows:

 

·    Primary endpoint (ORR by independent reviewer) has been met

·    With a median follow up of seven months, there is a clear clinical
benefit in patients with confirmed anti-PD1-resistant melanoma, with a 30% ORR
and a 65% DCR: superior to 2(nd) line Standard of Care in stage III/IV
melanoma of ~8% (continuing with anti-PD1 Ab) or 13% (second line ipilimumab).

·    Three hard-to-treat mucosal melanoma patients have achieved an ORR of
66% and DCR of 100%

·    High baseline LDH levels (>3xULN) predict progressive disease

·    Responses and stable diseases are durable

·    Study treatment has a manageable safety profile, with no patients
discontinuing due to adverse events

 

Next steps in the development of BO-112 include:

 

·    Initiation of a randomized Phase 2 study in 2nd-line melanoma is
planned in 2023

·    Highlight Therapeutics has initiated strategic partnerships
discussions with anti-PD1 companies interested in enhancing their anti-PD1
market potential

 

1.     IQVIA Global Oncology Report 2020

 

For more information, please contact:

 

 Highlight Therapeutics S. L.  info@highlighttherapeutics.com
 Marisol Quintero, CEO

 Mo PR Advisory                Tel: +44 (0) 7876 444977 / 07860 361746
 Mo Noonan/Jonathan Birt

 

Notes to editors

 

About Highlight Therapeutics

 

Highlight Therapeutics, formerly known as Bioncotech Therapeutics, is a
private, clinical-stage company dedicated to unlocking the full potential of
immuno-oncology. Our lead drug candidate BO-112 is a best-in-class RNA-based
therapy which has been demonstrated to initiate a powerful immune response,
leveraging a unique multi-target approach to turn 'cold' tumors 'hot' and
therefore visible to the immune system. It has the potential to rescue
patients who are resistant to current checkpoint inhibitor therapy, a very
large market opportunity. BO-112 is currently being investigated in a range of
clinical trials as a monotherapy and in combination with checkpoint
inhibitors. In addition to in-house research, Highlight Therapeutics has a
number of external collaborators, including Merck & Co and UCLA.

 

For more information, please visit www.highlighttherapeutics.com
(http://www.highlighttherapeutics.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGZGMDNFRGZZG